PVP Ventures Bets Big on Dialysis Care, Acquires 41% Stake in 7Med India

The target is to reach ₹50 crore in EBITDA over the next four years.

PVP Ventures has struck a deal to enter the renal care market with 7 Med India and Epitome Group of Hospitals.

The company has acquired an initial 41.23% stake, with a clear path to majority control within a year and a roadmap to increase its holding to 76%. The total investment to secure majority ownership is pegged at around ₹127 crore.

7Med India, headquartered in Delhi-NCR, operates 22 establishments across six states. Its presence spans in-hospital dialysis units, standalone dialysis centres, and four super-speciality hospitals under the Epitome brand, focused on nephrology and urology.

With a workforce of about 450, the chain currently generates an EBITDA of approximately ₹10 crore. Backed by PVP’s investment, the target is to reach ₹50 crore in EBITDA over the next four years. The deal requires no regulatory approvals.

The transaction marks a decisive strategic shift for PVP Ventures, which has been actively transitioning from a real estate-driven business to a healthcare and services-led model.

Earlier this year, the company acquired a majority stake in Biohygea (Medilabs), a diagnostics player. The addition of 7Med expands its healthcare platform into renal care, a high-growth segment in India, given the rising prevalence of chronic kidney disease and dialysis needs.

To support this transition, PVP is monetizing its real estate assets through joint development agreements with Brigade Enterprises and Casagrand. These projects are expected to generate over ₹2,000 crore in cash flows across the next six years. This capital will fund the company’s expansion into healthcare, including the growth of 7Med.

7Med’s immediate focus will be on Tier-2 and Tier-3 cities, where the demand for quality renal care is high but supply is limited. The company aims to expand its dialysis network, strengthen hospital infrastructure, and improve access to specialised kidney and urology care.

Dr Vijay Kher, co-founder of 7Med, said that, “this collaboration marks a significant milestone in the Healthcare sector, combining clinical excellence and innovative healthcare solutions to create a stronger, more future-ready organisation for delivering affordable, high-quality kidney care. We now aim to reach new geographies, expand patient-centric healthcare services, and enhance operational efficiencies through integrated resources.”

For PVP Ventures, the acquisition is a critical step in its ambition to build a technology-led “house of brands” in healthcare. Gaurav Davda, Head of M&A and Strategy at PVP, said that “This transaction represents a significant step in our journey in creating a powerful house of brands in Healthcare Services focused on Tier 2 and Tier 3 markets in key identified specialisations.”

“We welcome 7Med and its team into the PVP fold and look forward to enabling them to become a scaled national player in the near future,” He added.

Stay tuned for more such updates on Digital Health News